Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been published...
Asarina Pharma AB (publ) Q2 2022 Report released 2022-08-25 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME CEO Peter Nordkild: “If full clinical development is successful, Sepranolone will be the...
On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the “Loan Agreement”)...
Asarina Pharma AB (publ) Q1 2022 Report released 2022-05-25 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/...
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2021...
ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED 2022-04-06 17:25 Regulatory Annual
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that...